



Hospital Drug Carve Out List

Effective July 1, 2020, the Oklahoma Health Care Authority (OHCA) has changed the billing practices for certain high-investment drugs therapies. This change will improve access to expensive yet highly impactful drug therapies for the SoonerCare population.

These high-investment drugs which are “carved out” will still require a prior authorization (PA).

If the billing entity is purchasing the carve-out drug through their 340b program, then all applicable federal, supplemental, and value based rebates will be collected from the billing entity.

Please see Provider Letter 2020-04 for more information.

Drugs currently carved out:

Abecma® (idecabtagene vicleucel) (add date 4/8/21)

Breyanzi® (lisocabtagene maraleucel) (add date 7/1/21)

Carvytki (ciltacabtagene autoleucel) (add date 3/3/22)

Hemgenix (etranacogene dezaparvovec-drlb) (add date 4/1/23)

Kymriah® (tisagenlecleucel)

Luxturna® (voretigene neparvovec-rzyl)

Tecartus™ (brexucabtagene autoleucel) (add date 9/9/2020)

Spinraza® (nusinersen)

Yescarta® (axicabtagene ciloleucel)

Zolgensma® (onasemnogene abeparvovec-xioi)

If you have any questions, please contact the pharmacy helpdesk at (800) 522-0114, option 4 or (405) 522-6205, option 4.

Thank you for your continued support and the services you provide to SoonerCare members.

Updated 04/01/2023

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

P.O. Box 26901; ORI W-4403
Oklahoma City, OK 73126



WEBSITES

okhca.org
mysoonerca.org



PHONE

(800) 522-0114, option 4
Fax: (800) 224-4014